Increased expression of VEGF121/VEGF165–189 ratio results in a significant enhancement of human prostate tumor angiogenesis
Open Access
- 23 March 2007
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 120 (10) , 2096-2109
Abstract
Vascular endothelial growth factor (VEGF) is a proangiogenic factor upregulated in many tumors. The alternative splicing of VEGF mRNA renders 3 major isoforms of 121, 165 and 189 amino‐acids in humans (1 less amino‐acid for each mouse VEGF isoform). We have designed isoform specific real time QRT‐PCR assays to quantitate VEGF transcripts in mouse and human normal and malignant prostates. In the human normal prostate, VEGF165 was the predominant isoform (62.8% ± 5.2%), followed by VEGF121 (22.5% ± 6.3%) and VEGF189 (p < 0.001) (14.6% ± 2.1%). Prostate tumors showed a significant increase in the percentage of VEGF121 and decreases in VEGF165 (p < 0.01) and VEGF189 (p < 0.05). However, the amount of total VEGF mRNA was similar between normal and malignant prostates. VEGF164 was the transcript with the highest expression in the mouse normal prostate. Unlike human prostate cancer, tumors from TRAMP mice demonstrated a significant increase in total VEGF mRNA levels and in each of the VEGF isoforms, without changes in the relative isoform ratios. Morpholino phosphorodiamide antisense oligonucleotide technology was used to increase the relative amount of VEGF121 while proportionally decreasing VEGF165 and VEGF189 levels in human prostate cell lines, through the modification of alternative splicing, without changing transcription levels and total amount of VEGF. The increase in the VEGF121/VEGF165–189 ratio in PC3 cells resulted in a dramatic increase in prostate tumor angiogenesis in vivo. Our results underscore the importance of VEGF121 in human prostate carcinoma and demonstrate that the relative expression of the different VEGF isoforms has an impact on prostate carcinogenesis.Keywords
This publication has 41 references indexed in Scilit:
- Vascular Targeting of Ocular Neovascularization with a Vascular Endothelial Growth Factor121/Gelonin Chimeric ProteinMolecular Pharmacology, 2005
- VEGF as a Therapeutic Target in CancerOncology, 2005
- Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanismsOncogene, 2004
- Stimulation of angiogenesis by Ras proteinsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2004
- Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in TumorsThe American Journal of Pathology, 2003
- Autochthonous mouse models for prostate cancer: past, present and futureSeminars in Cancer Biology, 2001
- Laminin-1 and ?6?1 integrin regulate acinar morphogenesis of normal and malignant human prostate epithelial cellsThe Prostate, 2001
- Role of vascular endothelial growth factor in the regulation of angiogenesisKidney International, 1999
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivoCell, 1987